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Summary 
A highly specific and sensitive radioimmunoassay (R/A) has been established for 
determination of endothelin-3 like immunoreactivity in human plasma to 
investigate its possible role in hemodynamic alterations due to liver disease. 
Crossreactivity with other endothelin isoforms was always below 4 %, the lower 
detection limit following extraction on Sep-Pak C18 cartridges was 0.5 pg/ml. The 
concentration of endothelin-3 (mean + SEM) was 4.16 + 0.56 pg/ml (n = 13) in 
plasma of patients with cirrhosis of the liver, three fold higher than in age matched 
controls (1.35 + 0.27 pg/ml, n = 12, p < 0.01). Plasma immunoreactivity was
confirmed to be endothelin-3 related by reverse-phase HPLC. These data could 
suggest a role of plasma endothelin-3 in circulatory changes, as they occur in 
cirrhosis of the liver. 
Endothelin-1 (ET-I), a 21 amino acid peptide with potent vasoconstrictor activity (I) has 
been investigated in a variety of cardiovascular nd endocrine diseases to establish its possible 
role in the pathophysiology of these disorders (for review see 2,3). As yet there is only scarce 
information about endothelin-3 (ET-3) which differs from ET-1 by six amino acids (4). However, 
determination of circulating ET-3 is of considerable interest regarding the different 
pharmacological properties of ET-3 and ET-1 (4-6). ET-3 has been shown to act as a vasodilator 
(7,8) and therefore may play a role different from ET-1 in various pathophysiological conditions. 
Hemodynamic changes in cirrhosis of the liver are characterized by peripheral vasodilation (9),
however the responsible agent has not been identified so far. Vasodilating substances which are 
released into the intestinal circulation and cleared to a lesser extent by the cirrhotic liver are 
candidates in this respect. Since the intestine has been shown to be a major site of ET-3 synthesis 
(10) one might speculate, that ET-3 plasma levels could be increased in chronic fiver disease, thus 
contributing to the aforementioned hemodynamic alterations. Therefore we established a RIA to 
investigate circulating ET-3 in patients with cirrhosis of the liver. 
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Materials and Methods 
Blood samples: Venous blood samples were obtained from 12 healthy volunteers (age 52 + 4 
years) and 13 patients with cirrhosis of the liver (54 ± 3 years old). Blood was transferred into 
precooled tubes containing EDTA (lmg/ml) and then centrifuged at 1500 x g for 10 min. at 4°C. 
Samples were stored at -70°C. 
Plasma extraction: Plasma samples (1 ml) were acidified with 2 ml acetic acid (4 %) or 1 ml of 
trifluoroacetic acid (TFA) (0.1%) and centrifuged at 2500 x g for 10 min. The supernatant was 
applied to Sep-Pak C18 cartridges (Waters, Milford, MA), which had been activated with 10 ml of 
acetone, water, methanol and acetic acid (4 %) consecutively. Cartridges were then washed with 
10 ml of 50 mM TrisHCl buffer (pH 7.4) and eluted with 3 ml of acetonitrile / 0.026 M 
ammonium acetate (60 % / 40 %). Eluates were dried down in a speed-vac oncentrator. 
Extraction recovery was evaluated by adding increasing concentrations of synthetic ET-3 (Nova 
Biochem, Laufelfingen, Switzerland) to plasma samples prior to extraction. 
Radioimmunoassay: RIA for ET-3 was carried out in 0.02 M phosphate buffer (pH 7.4), 
containing 0.15 M NaC1, 0.01% bovine serum albumin, 0.1% gelatine, 0.01% thimerosal and 
0.1% Triton X100. Samples or diluted standard of ET-3 were reconstituted to 350 lal and 100 gl 
of antibody RAS 6911N (Peninsula, London, UK, final dilution 1: 100000) was added. After a 
24h incubation period 10000 cpm of [125J]ET-3 (Amersham, Braunschweig, FRG, specific 
activity 2000 Ci/mmol), diluted in 50 gl of assay buffer were added, followed by another 24 h 
incubation. Separation of the bound ligand was then performed by adsorption of the free ligand to 
albumin coated charcoal, followed by centrifugation. The supernatant was counted in a LKB 
gamma counter (Turku, Finland). 
Reverse-phase HPLC: Pooled plasma was extracted as described above. The dried residue was 
reconstituted in 100 gl 0.1% TFA, loaded on a C18 reverse phase HPLC column (0.39 x 30 cm, 
~tBondapak, Waters, Milford, MA) and eluted with a linear gradient of acetonitrile from 20 to 50 
% during 60 rain. in 0.1% TFA (flow rate 1 ml/min., fraction size 1 ml). Collected fractions were 
lyophilized and subjected to RIA. 
Statistical analysis: Data are given as mean and standard error. Plasma levels were not corrected 
for recovery. Mean values were compared by the student's t-test. A p-value of less than 0.05 was 
considered as statistically significant. 
Results 
The lower detection limit of the established RIA was 0.5 pg/ml plasma. Serial dilutions of 
extracted plasma from healthy volunteers and cirrhotic patients paralleled the standard curve (fig. 
1). Intra- and interassay variations, employing eight samples, were 10.7 + 1.9 % (n = 5) and 16.5 
± 2.3 % (n = 4), respectively. Crossreactivity of antibody RAS 6911N was 2.6 % for ET-1, 2.7 % 
for ET-2, 3.7 % for big ET-1 and 100 % for the precursor big ET-3; the specificity of the 
antiserum was furthermore proven by reverse-phase HPLC of ET-3 like immunoreactivity. 
Common extraction procedures for ET-1, using 4 % acetic acid for dilution of plasma samples, 
yielded poor recovery rates: 37.9 %, 21.5 % and 7.7 % for 3.9, 7.8 and 31.3 pg ET-3, respectively. 
Therefore we diluted plasma with 0.1% TFA followed by centrifugation prior to application onto 
extraction cartridges. Thereby, extraction recoveries of 3.9, 7.8 and 31.3 pg synthetic ET-3 were 
raised to 89.3 + 1.2 %, 75.1 + 8.9 % and 58.3 + 10.6 % in controls (n = 5) and 93.1 + 6.8 %, 92.7 
+7.8 % and 72.2 ± 8.1% in cirrhotic patients (n = 5). 
Circulating ET-3 was significantly higher (p < 0.01) in patients with cirrhosis (4.16 + 0.56 pg/ml) 
as compared to age matched healthy controls (1.35 + 0.27 pg/ml, fig. 2). Immunoreactivity was 
shown to be ET-3 related by reverse-phase HPLC (fig. 3). 
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FIG. 2 
Plasma ET-3 concentrations in healthy subjects (n = 12) and in patients with 
cirrhosis of the liver (n = 13). The scattered line indicates the lower detection limit 
of the radioimmunoassay. Plasma concentrations in patients (4.16 + 0.56 pg/ml) 
were significantly (p < 0.01) higher than in controls (1.35 + 0.27 pg/ml). 
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Discussion 
We have established a sensitive RIA for determination of ET-3 in human plasma with a 
lower detection limit of 0.5 pg/ml. The validity of this assay was demonstrated by the parallelity 
of plasma dilution curves to the standard curve. Intra- and interassay experiments showed the 
reliability and reverse-phase HPLC the specificity of the assay. Recoveries were considerably 
improved by a modification of the common extraction procedure, possibly as a result of 
precipitation of plasma proteins. Recovery rates were not significantly different between plasma 
of patients and controls. 
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FIG. 3 
Reverse-phase HPLC analysis of immunoreactive ET-3 in plasma from patients 
with cirrhosis of the liver. Arrows indicate the elution positions of ET-1 (1), ET-2 
(2), ET-3 (3) and big ET-1 (B). 
Mean plasma concentrations of ET-3 in healthy adults were found to be 1.35 pg/ml, higher than 
the values detected by a sandwich-enzyme immunoassay (11). In cirrhotic patients ET-3 was 
raised threefold to a mean concentration of4.16 pg/ml. 
Several mechanisms might account for increased ET-3 in cirrhosis. Elevated ET-3 plasma levels 
have been reported after sympathetic activation in healthy volunteers ubsequent to strenuous 
exercise (12). Patients with cirrhosis of the liver exhibit an activation of the renin-angiotensin-al- 
dosterone system (13) and of the sympathetic nervous ystem (9). An increase of plasma ET-3 
could therefore be interpreted as a result of stimulated synthesis and release following sympathetic 
activation. On the other hand, ET-3 elevations could contribute to the vasodilation i  cirrhosis and 
thus stimulate an activation of the sympathetic nervous system, 
Plasma concentrations of peptides are determined not only by synthesis and release, but also by 
clearance and degradation (14). Therefore, another mechanism leading to increased ET-3 plasma 
levels could be a decreased renal clearance of ET-3, as described in patients undergoing chronic 
hemodialysis (15). The patients included in the present study, however, exhibited normal renal 
function. 
Finally a decreased hepatic extraction of gut-derived ET-3 or a hepatic release in cirrhosis of the 
liver may be responsible for the elevated ET-3 plasma levels. The role of the liver in clearance of 
endothelins, however, has not been established so far and remains to be elucidated. Nevertheless, 
the finding of increased ET-3 plasma concentrations could suggest a role of this biologically 
active peptide in the hemodynamic changes of patients with cirrhosis of the liver. 
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